HIV-Specific Differences in Outcome of Squamous Cell Carcinoma of the Anal Canal: A Multicentric Cohort Study of HIV-Positive Patients Receiving Highly Active Antiretroviral Therapy

Oehler-Jänne, Christoph; Huguet, F.; Provencher, Sawyna; Seifert, Burkhardt; Negretti, Laura; Riener, Marc‐Oliver; Bonet, Marta; Allal, Abdelkarim Said; Ciernik, I. Frank

doi:10.1200/jco.2007.15.2348

Cited by 179 publications

(164 citation statements)

References 35 publications

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…There was a discrepancy in the number of patients with SCC of the anus in the HIV positive cohort (68%) compared to the number of patients in the HIV negative cohort (31%). This supports past findings that HIV positive individuals have a higher risk of developing anal SCC than HIV negative individuals [4,5,[15][16][17].…”

Section: Discussionsupporting

confidence: 82%

“…Specifically, the 5-year survival rates for HIV negative and HIV positive patients were 57% and 58%, respectively, which is not significantly different. Other retrospective cohort studies have demonstrated similar 5-year survival rates (61%-71%) in HIV positive patients [16,18,19,20]. In 1996, before the widespread use of HAART, poorer outcomes were demonstrated with HIV positive patients with anal SCC.…”

Section: Discussionmentioning

confidence: 69%

See 1 more Smart Citation

Anal Squamous Cell Carcinoma in African Americans with and without HIV: A Comparative Study

Clark¹

2015

J Can Epi Treat

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 69%

Anal Squamous Cell Carcinoma in African Americans with and without HIV: A Comparative Study

Clark¹

2015

J Can Epi Treat

View full text Add to dashboard Cite

“…Similarly to other studies (17)(18)(19)(20), we also demonstrated that tumor size, nodal status and HIV status are the most significant prognostic factors for patients with anal SCC. On multivariate analysis, patients with tumors >5 cm as well as those with HIV+ had almost 3 times more risk of developing a disease event and at least 4 times the risk of dying from anal cancer.…”

Section: Discussionsupporting

confidence: 61%

A comparison between 5-fluorouracil/mitomycin and capecitabine/mitomycin in combination with radiation for anal cancer

Peixoto

Wan²,

Schellenberg³

et al. 2016

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

Background: There are no randomized phase III trials comparing 5-fluorouracil/mitomycin (FM) versus capecitabine/mitomycin (CM) in combination with radiotherapy (RT) for locally advanced anal cancer. We aim to evaluate the outcomes of patients treated with FM and CM at our institution. Conclusions: In our population-based study, CM and FM concomitant with RT achieved similar DFS and ACSS. Substitution of capecitabine for infusional 5-FU may therefore be a reasonable option for patients and physicians who prefer to avoid the inconvenience and potential complications of a central infusional device.

show abstract

“…This excess of mortality is probably imputable to various factors that continue to distinguish HIV-infected patients from the general population even during the HAART era: a more advanced cancer stage at diagnosis, 11,12,[18][19][20] a more aggressive cancer behavior 33 and a higher proportion of concomitant comorbidities (especially viral hepatitis and related hepatic impairment).…”

Section: 1%)]mentioning

confidence: 99%

Ten‐year survival among HIV‐1‐infected subjects with AIDS or non‐AIDS‐defining malignancies

Spagnuolo

Galli

Salpietro

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

Few data are available regarding the 10‐year survival among subjects with HIV and cancer. The aim of this study was to evaluate the 10‐year survival of HIV‐infected subjects with AIDS‐defining malignancies (ADM) or non‐AIDS‐defining malignancies (NADM). This was a single center, retrospective, observational study of subjects with HIV infection and a subsequent cancer diagnosis; the data were collected from January 1991 to April 2010. Malignancies were divided into ADM or NADM on the basis of the Centre of Diseases Control‐1993 classification. Survival curves were estimated using Kaplan–Meyer method and compared by the log‐rank test. Six hundred and fifteen (9.5%) of the 6,495 subjects recorded in the San Raffaele Infectious Diseases Database developed a malignancy: 431 (70%) an ADM and 184 (30%) a NADM. In the case of ADM, survival was more favorable when cancer was diagnosed during post‐highly active antiretroviral therapy (HAART) era (10‐year survival: 43.2% ± 4.4%) than when diagnosed during the pre‐HAART era (10‐year survival: 16.4% ± 2.7%; log‐rank test: p < 0.001). The same was true in the case of NADM (10‐year survival: 44.7% ± 5.5% vs. 33.3 ± 9.6%; log‐rank test: p = 0.03). An evaluation of survival probability by cancer type showed higher survival rates during the post‐HAART era in the case of non‐Hodgkin lymphoma (10‐year survival: 42.1% ± 5.3% vs. 11.4% ± 3.3%; log‐rank test: p = <0.001), Kaposi's sarcoma (10‐year survival: 44.0% ± 8.4% vs. 23.5% ± 3.9%; log‐rank test: p < 0.001) and Hodgkin's disease (10‐year survival: 49.5% ± 14.5% vs. 40.0% ± 12.7%; log‐rank test: p = 0.005). Despite the better cancer prognosis during the post‐HAART era, the 10‐year survival of HIV‐infected subjects with an ADM or NADM is poor.

show abstract

HIV-Specific Differences in Outcome of Squamous Cell Carcinoma of the Anal Canal: A Multicentric Cohort Study of HIV-Positive Patients Receiving Highly Active Antiretroviral Therapy

Cited by 179 publications

References 35 publications

Anal Squamous Cell Carcinoma in African Americans with and without HIV: A Comparative Study

Anal Squamous Cell Carcinoma in African Americans with and without HIV: A Comparative Study

A comparison between 5-fluorouracil/mitomycin and capecitabine/mitomycin in combination with radiation for anal cancer

Ten‐year survival among HIV‐1‐infected subjects with AIDS or non‐AIDS‐defining malignancies

Contact Info

Product

Resources

About